ALAMEDA, Calif.-- (BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that ...
BioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient Enrollment in the US BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results